MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.250
+0.100
+2.41%
Closed 19:02 11/25 EST
OPEN
4.190
PREV CLOSE
4.150
HIGH
4.330
LOW
4.120
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
12.44
52 WEEK LOW
1.800
MARKET CAP
465.42M
P/E (TTM)
-3.9517
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vaccine access and distribution a big topic at G20
At this weekend's summit in Riyadh, G20 leaders pledged to ensure fair distribution of COVID-19 vaccines, drugs and tests around the world so that poorer countries were not left out
Seekingalpha · 4d ago
FDA plans early advisory meetings in December to discuss COVID-19 vaccines - CNBC
The FDA is said to have asked its vaccines advisory committee to plan meetings in early in December to discuss COVID-19 vaccines ahead of potential authorization, CNBC.The advisory group may
Seekingalpha · 11/19 10:02
Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T.
PR Newswire · 11/17 21:05
Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate
Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies Corporation (NASDAQ:DVAX), a US-based vaccine focused biopharmaceutical company, and Baylor College of
Benzinga · 11/16 11:03
Analysts Just Shipped A Dazzling Upgrade To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates
Celebrations may be in order for Dynavax Technologies Corporation (NASDAQ:DVAX) shareholders, with the analysts...
Simply Wall St. · 11/10 10:33
Dynavax Technologies Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates
It's been a pretty great week for Dynavax Technologies Corporation (NASDAQ:DVAX) shareholders, with its shares surging...
Simply Wall St. · 11/07 13:58
ACB, TTD, TLRY and NET among premarket gainers
FTS International (FTSI) +67% after successful confirmation of plan of reorganization.Mogo (MOGO) +58% after announcing MogoSpend supports Apple Pay, Google Pay and Samsung Pay.GoPro (GPRO) +21% on Q3 results.Glu Mobile (GLUU) +17% on Q3 results.Aurora Cannabis (ACB) +16%.Applied
Seekingalpha · 11/06 13:22
Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25.00% and 21.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/05 23:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Techs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DVAX stock price target is 16.00 with a high estimate of 20.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 246
Institutional Holdings: 105.75M
% Owned: 96.57%
Shares Outstanding: 109.51M
TypeInstitutionsShares
Increased
49
14.80M
New
69
1.72M
Decreased
40
9.13M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Independent Director
Andrew Hack
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Michael Ostrach
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Steven Gersten
Senior Vice President/Director of Human Resources
Jeff Coon
Senior Vice President
Robert Janssen
Chief Accounting Officer
Justin Burgess
Director
Julie Eastland
Director
Brent MacGregor
Director
Peter Paradiso
Independent Director
Francis Cano
Independent Director
Daniel Kisner
Independent Director
Arnold Oronsky
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DVAX
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.